RESEARCH TRIANGLE PARK, N.C. – July 9, 2010 – Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced that it has been named the 2010 Asia Pacific Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This is the third time in the last five years that Quintiles Asia-Pacific has been honored by the leading growth partnership firm for its performance in the region. Presented at the recent 2010 Frost & Sullivan Asia Pacific Best Practices Awards banquet in Singapore, the award honors the company that exhibited excellence in growth strategy and implementation, innovation as well as overall customer and market leadership.

“On behalf of our network of more than 3,000 talented and engaged clinical professionals throughout Asia-Pacific, I am honored to accept this award from Frost & Sullivan,” said Anand Tharmaratnam, Senior Vice President and Head of Clinical Development for Quintiles Asia-Pacific. “As biopharmaceutical companies increase their focus on Asia, our combination of regional expertise and global experience has never been more important. This award recognizes Quintiles’ unique strengths and acknowledges our leadership in helping customers navigate risk and seize opportunities in this New Health landscape.”

Elaborating on Frost & Sullivan’s choice for the award, Rhenu Bhuller, Vice President for the Asia Pacific Pharmaceuticals and Biotechnology practice at Frost & Sullivan said, “Quintiles is seeing success through its foresight on the potential of the Asia-Pacific region, which provides a large pool of accessible and genetically diverse patients, scientific talent and proximity to high growth pharmaceutical markets. As one of the region’s early pioneers in clinical development, the company has grown its broad range of integrated service offerings in clinical development, and its links with some of the region’s largest clinical institutions. Its geographic presence in key locations within Asia-Pacific has enabled biopharmaceutical companies to capitalize on the region’s benefits from a demographic and cost effectiveness perspective, and has made Quintiles one of the fastest growing clinical development companies in the region.”

She further adds that as biopharmaceutical companies increasingly value the advantage of an integrated service platform, Quintiles’ strong track record of providing quality services across the pharmaceutical value chain has enhanced its ability to cross-sell new services to both its global and regional clients.

An industry pioneer and innovator, Quintiles opened its first office in the Asia-Pacific market in 1993. Since that time, the company has grown to more than 20 offices in 14 countries throughout the region. 

During that same timeframe, Quintiles has conducted 1,300 studies involving greater than 9,000 sites and more than 185,000 patients in the region. Through these efforts and experience, Quintiles is able to provide its customers with unmatched expertise and experience across a wide range of therapeutic areas, including cardiovascular disease, oncology, neurology, infectious disease and others.
Tharmaratnam said, “We are in the midst of new era in the clinical research industry and Quintiles is proud to be at the center of this innovation not only here in Asia-Pacific, but around the world.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com